<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803240</url>
  </required_header>
  <id_info>
    <org_study_id>LT2280-PIV-0718</org_study_id>
    <nct_id>NCT04803240</nct_id>
  </id_info>
  <brief_title>Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment</brief_title>
  <official_title>Survey: Evaluation of Ocular Surface Disease Symptoms and Patient Satisfaction With Thealoz® Duo After 84 Days of Daily Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iris Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoires Thea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centre, international, non-interventional, prospective survey&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess after 84 days, on a large scale patient population, the evaluation of ocular&#xD;
      surface diseases and the satisfaction of dry eye disease (DED) treatment naïve patients or&#xD;
      those who had to switch for tolerance, dissatisfaction or efficacy reasons to Thealoz® Duo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OSDI</measure>
    <time_frame>84 days</time_frame>
    <description>Change from baseline for patient symptoms using the ocular surface disease index (OSDI©) questionnaire at Day 84. The OSDI is assessed on a scale of 0 to 100, with higher scores representing greater disability.</description>
  </primary_outcome>
  <enrollment type="Actual">310</enrollment>
  <condition>Dry Eye</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thealoz Duo</intervention_name>
    <description>Non applicable</description>
    <other_name>sodium hyaluronate and trehalose</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All dry eye patients who require artificial tears or need to change their current&#xD;
        artificial tears for any reason (i.e. due to dissatisfaction or low efficacy, etc…)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All dry eye patients who require artificial tears or need to change their current&#xD;
             artificial tears for any reason (i.e. due to dissatisfaction or low efficacy, etc…)&#xD;
&#xD;
          -  Outpatients of either sex, aged at least 18 years&#xD;
&#xD;
          -  Patients informed of the objectives of the survey and agreeing to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of cyclosporine, lifitegrast, tacrolimus, sirolimus within last 3 months and&#xD;
             during the survey&#xD;
&#xD;
          -  Use of topical ophthalmological treatments (glaucoma, etc…)&#xD;
&#xD;
          -  Use of lacrimal plugs&#xD;
&#xD;
          -  Ocular surgery in the last 12 months&#xD;
&#xD;
          -  Concomitant use of corticosteroids&#xD;
&#xD;
          -  Concomitant use of autologous serum or any blood derivatives&#xD;
&#xD;
          -  Severe blepharitis&#xD;
&#xD;
          -  Severe dry eye associated to&#xD;
&#xD;
               -  Eyelid malposition&#xD;
&#xD;
               -  Corneal dystrophy&#xD;
&#xD;
               -  Ocular neoplasia&#xD;
&#xD;
               -  Sjogren syndrome&#xD;
&#xD;
               -  Any systemic pathologies&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Antonio MATEO, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip BUCKHURST, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Plymouth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Plymouth</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

